pharmaceutica

Pharmaceutica is a multinational pharmaceutical company headquartered in Madrid, Spain. Established in 1987 by a consortium of regional generic drug manufacturers, the company has grown to become one of the leading suppliers of low‑cost pharmaceutical products across Europe, Latin America, and parts of Asia. Pharmaceutica focuses on the development, production, and distribution of generic versions of a wide range of therapeutic agents, including cardiovascular, antidiabetic, and central nervous system medications.

The firm operates a portfolio of research and development facilities that emphasize cost‑effective drug formulation and biosimilar production. In addition to its generic pipeline, Pharmaceutica has an active innovations division that invests in late‑stage clinical trials for specialty medicines in oncology and rare disease areas. Its manufacturing network consists of eight GMP‑compliant production sites, each equipped with automated assembly lines and advanced quality control systems.

Pharmaceutica has pursued strategic partnerships and acquisitions to expand its global footprint. Notable transactions include the 2012 purchase of a U.S. biosimilar manufacturer, which broadened the company’s presence in North America, and the 2019 joint venture with a Russian generic producer to enter the Eastern European market. The company’s corporate social responsibility initiatives focus on improving access to essential medicines in underserved regions, providing subsidized drug pricing, and supporting local healthcare education programs.

As of 2025, Pharmaceutica reported annual revenues exceeding €2.3 billion and a market capitalization of approximately €12 billion. The company remains listed on the Madrid Stock Exchange and is a constituent of the Spanish mid‑cap benchmark. Its leadership structure includes a CEO, a board of directors, and separate committees for audit, risk, and sustainability matters.